PRESS RELEASE

Synucure Therapeutics Holds Inaugural Meeting of Its Scientific Advisory Board

MONTREAL, August 21, 2025 – Synucure Therapeutics is pleased to announce that the first Scientific Advisory Board (SAB) meeting took place on August 1st. This is an important milestone for the company, which specializes in developing a Disease Modifying Therapy (DMT) for Parkinson's disease and other neurogenerative disorders, notably through the use of cysteamine and innovative biomarkers aimed at improving diagnosis.

The Board, composed of internationally recognized experts in neurology, neurogenetics, movement disorders, and neuropsychiatry, will guide Synucure Therapeutics in its scientific and clinical directions. Its mission: to inform the company's strategic decisions and advance solutions that address real medical needs in Parkinson's disease and other neurodegenerative disorders.

Scientific Advisory Board Members

- **Dr. Camila Aquino, MD, MSc, PhD**
  Neurologist specialized in movement disorders, Dr. Camila Aquino leads the Deep Brain Stimulation (DBS) program at the University of Calgary. A recognized expert in Parkinson's disease, essential tremor, and dystonia, she also develops innovative non-invasive therapies such as MRI-guided focused ultrasound.

- **Prof. Dominique Bonneau, MD, PhD**
  Medical geneticist and professor, he heads the Clinical Genetics Unit at Angers University Hospital. A recognized expert in hereditary diseases of the nervous system, he is a member of the French National Reference Center for Neurogenetic Diseases. He conducts clinical research on Huntington's disease and is the principal investigator of a clinical trial that evaluated cysteamine in this condition.

- **Prof. Roger A. Barker, MD, PhD, FMedSci**
  Professor of Clinical Neurosciences at the University of Cambridge and honorary consultant neurologist at Addenbrooke's Hospital. He is lead researcher at the Alborada Drug Discovery Institute and the John van Geest Centre for Brain Repair. He directs the regional Huntington's disease clinic and chairs the neurodegeneration committee at LifeArc.

- **Dr. Ray Dorsey, MD, MBA**
  Director of the Center for the Brain & the Environment at Atria Health and Research Institute. Co-author of *Ending Parkinson's Disease* and *The Parkinson's Plan*, he has led the Movement Disorders Division at Johns Hopkins, the Center for Health + Technology at the University of Rochester and chaired the Huntington Study Group. Named a "Champion of Change" by the White House in 2015.

- **Prof. Christopher A. Ross, MD, PhD**
  Professor of Neuropsychiatry at Johns Hopkins University School of Medicine, director of the Neurobiology Division and Huntington's Disease Center. A recognized expert in neurobiology and neurogenetics, he leads major research on early mechanisms of Huntington's disease.

Quotes:

"A proud moment for Synucure, with the first meeting of our Scientific Advisory Board. A great opportunity for us to demonstrate how robust our science is. Facing challenges is part of the journey, and we are grateful to count on the expertise of such high-level scientific advisors. Their collaboration will be instrumental in helping us achieve our mission."

— **Sylvain Chrétien**, CEO and cofounder of Synucure Therapeutics.

"We are absolutely thrilled to benefit from the expertise and knowledge of our newly appointed Scientific board members, whom are all world-leading neurologists/scientists. Our first recent meeting proved to be critical in guiding Synucure in the next steps to take our lead compound, SYN-001 (novel cysteamine formulation), to the clinic to treat neurodegenerative disorders."

— **Dre Francesca Cicchetti,** Chief Science Officer and cofounder of Synucure Therapeutics, Professor at the Faculty of Medicine at Université Laval and a Neuroscience Researcher at the CHU de Québec – Université Laval Research Center.

About Synucure Therapeutics

Synucure Therapeutics, founded in 2021, is a Canadian biotech firm researching degenerative brain disorders. Synucure's main objective is to pursue the promising preclinical work conducted by Dr. Francesca Cicchetti on the use of cysteamine. This research has shown, in various animal and cellular models, that this drug can prevent and/or reverse a number of characteristics associated to Parkinson's disease (PD). The firm has several research projects under way, including developing a tool to better diagnose PD based on blood biomarkers.

To learn more, visit www.synucure.com and follow us on LinkedIn.